Literature DB >> 8335042

Pharmacokinetics of endogenous substances: some problems and some solutions.

A Marzo1, A Rescigno.   

Abstract

The paper deals with the most relevant aspects related to the pharmacokinetics of endogenous substances. Two different views are presented in order to focus on two aspects of the problem, the physiological background of these substances and the need for empirical or tailored models to process pharmacokinetic data. Very often endogenous substances follow saturable enzyme biotransformation, reversible interconversion, active and diffusional transports, renal threshold, endogenous synthesis plus dietary supply with possible balancement between these two factors, feedback processes, asymmetric distribution with specific body storage, and gender differences. These mechanisms allow the body to preserve and restore homeostatic equilibria of endogenous substances. The most relevant problem in pharmacokinetics of these substances is the presence of baseline concentration which needs to be carefully defined also for possible rhythms related to age, sex, diet, night and day periods. Theoretical considerations are presented for the management of pharmacokinetic analysis of these substances, which only rarely follow linear processes. Throughout the text various practical examples are considered.

Mesh:

Year:  1993        PMID: 8335042     DOI: 10.1007/BF03220010

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  12 in total

Review 1.  Enzymes in stereoselective pharmacokinetics of endogenous substances.

Authors:  A Marzo; G Cardace; E Arrigoni Martelli
Journal:  Chirality       Date:  1992       Impact factor: 2.437

2.  Bioequivalence.

Authors:  A Rescigno
Journal:  Pharm Res       Date:  1992-07       Impact factor: 4.200

3.  Area under the curve, bioavailability, and clearance.

Authors:  A Rescigno; A Marzo
Journal:  J Pharmacokinet Biopharm       Date:  1991-08

Review 4.  Carnitine deficiency.

Authors: 
Journal:  Lancet       Date:  1990-03-17       Impact factor: 79.321

5.  Metabolism and disposition of intravenously administered acetyl-L-carnitine in healthy volunteers.

Authors:  A Marzo; E Arrigoni Martelli; R Urso; M Rocchetti; V Rizza; J G Kelly
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

6.  Bioavailability of potassium from three dosage forms: suspension, capsule, and solution.

Authors:  A P Melikian; L K Cheng; G J Wright; A Cohen; R E Bruce
Journal:  J Clin Pharmacol       Date:  1988-11       Impact factor: 3.126

Review 7.  Gonadotropin-steroid interrelationships.

Authors:  R L Wiele; I Dyrenfurth
Journal:  Pharmacol Rev       Date:  1973-06       Impact factor: 25.468

8.  Metabolic interconversions of different forms of vitamin B6.

Authors:  S Johansson; S Lindstedt; H G Tiselius
Journal:  J Biol Chem       Date:  1974-10-10       Impact factor: 5.157

9.  The effect of enteral carnitine administration in humans.

Authors:  B Li; M L Lloyd; H Gudjonsson; A L Shug; W A Olsen
Journal:  Am J Clin Nutr       Date:  1992-04       Impact factor: 7.045

10.  Dissimilar effects in acute toxicity studies of CDP-choline and choline.

Authors:  J Agut; E Font; A Sacristán; J A Ortiz
Journal:  Arzneimittelforschung       Date:  1983
View more
  6 in total

1.  A comparison of the bioequivalence of two formulations of epoetin alfa after subcutaneous injection.

Authors:  Akashi Togawa; Takanori Tanaka; Satoru Nagashima; Hiroyuki Keta; Yasue Kobayashi; Yasuhiro Nishikawa; Masanobu Yanai; Hideji Tanaka
Journal:  Br J Clin Pharmacol       Date:  2004-09       Impact factor: 4.335

Review 2.  Synergic development of pharmacokinetics and bioanalytical methods as support of pharmaceutical research.

Authors:  M Marzo; R Ciccarelli; P Di Iorio; P Giuliani; F Caciagli; A Marzo
Journal:  Int J Immunopathol Pharmacol       Date:  2015-12-18       Impact factor: 3.219

3.  Inhibition of melatonin metabolism in humans induced by chemical components from herbs and effective prediction of this risk using a computational model.

Authors:  Chao Wang; Xiaokui Huo; Xiangge Tian; Min Xu; Peipei Dong; Zhilin Luan; Xiaobo Wang; Baojing Zhang; Bo Zhang; Shanshan Huang; Sa Deng; Xiaochi Ma
Journal:  Br J Pharmacol       Date:  2016-10-10       Impact factor: 8.739

4.  The population pharmacokinetics of recombinant- and urinary-human follicle stimulating hormone in women.

Authors:  M O Karlsson; J R Wade; E Loumaye; A Munafo
Journal:  Br J Clin Pharmacol       Date:  1998-01       Impact factor: 4.335

Review 5.  Some pharmacokinetic considerations about homeostatic equilibrium of endogenous substances.

Authors:  A Marzo; A Rescigno; E Arrigoni Martelli
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Apr-Jun       Impact factor: 2.441

6.  Pharmacokinetic differentiation of drug candidates using system analysis and physiological-based modelling. Comparison of C.E.R.A. and erythropoietin.

Authors:  Peter Veng-Pedersen; Kevin J Freise; Robert L Schmidt; John A Widness
Journal:  J Pharm Pharmacol       Date:  2008-10       Impact factor: 3.765

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.